{"title":"Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian Cancer.","authors":"Stavroula A Paschou, Angeliki Andrikopoulou, Nikoletta Mili, Anna Svarna, Maria Kaparelou, Katerina Stefanaki, Nikolaos Dedes, Efstathia Liatsou, Nikolaos Thomakos, Dimitrios Haidopoulos, Theodora Psaltopoulou, Efstathios Kastritis, Flora Zagouri, Meletios-Athanasios Dimopoulos, Michalis Liontos","doi":"10.3390/nu17030556","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/objectives: </strong>Survival rates for ovarian cancer remain distressingly low. Despite established prognostic factors, the need to identify modifiable parameters to influence survival outcomes is imperative. Overweight and obesity, both prevalent conditions, have been implicated in cancer development and potentially poor survival. However, conflicting data on the associations of body mass index (BMI) with progression-free survival (PFS) and overall survival (OS) in ovarian cancer patients necessitate further exploration. This study aims to investigate the prognostic role of BMI before chemotherapy in women with ovarian cancer, specifically focusing on PFS and OS.</p><p><strong>Methods: </strong>A retrospective analysis encompassed 1,136 patients diagnosed with ovarian carcinomas between 1995 and 2018. Patients were categorized based on BMI at presentation, and a comprehensive examination of clinicopathological, treatment, and survival data was conducted.</p><p><strong>Results: </strong>In the patient population, normal weight patients (BMI < 25 kg/m<sup>2</sup>) demonstrated a median PFS of 12.8 months (95% CI 11.7-13.9 months), while overweight/obese patients (BMI ≥ 25 kg/m<sup>2</sup>) exhibited a significantly longer median PFS of 14.9 months (95% CI 13.6-16.4 months, <i>P</i> = 0.006). No statistically significant difference was noted in median OS between the two BMI groups. Subgroup analysis for different histological subtypes revealed a statistically significant benefit for overweight and obese patients with serous and endometrioid histology (mPFS 12.9 months, 95% CI 11.7-14.0 vs. 15.6 months, 95% CI 13.9-17.3, <i>P</i> = 0.012 and 14.6 months 95% CI 13.7-15.5 vs. 25.6 months, 95% CI 9.5-41.7, <i>P</i> = 0.031, respectively). Additionally, BMI ≥ 25 kg/m<sup>2</sup> demonstrated a significant advantage in advanced-stage disease.</p><p><strong>Conclusions: </strong>The study underscores the intricate association between BMI and ovarian cancer prognosis. While a statistically significant difference in progression-free survival was noted between normal weight and overweight/obese patients, with the latter group experiencing a survival benefit, no such difference was observed in overall survival.</p>","PeriodicalId":19486,"journal":{"name":"Nutrients","volume":"17 3","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11820758/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrients","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/nu17030556","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background/objectives: Survival rates for ovarian cancer remain distressingly low. Despite established prognostic factors, the need to identify modifiable parameters to influence survival outcomes is imperative. Overweight and obesity, both prevalent conditions, have been implicated in cancer development and potentially poor survival. However, conflicting data on the associations of body mass index (BMI) with progression-free survival (PFS) and overall survival (OS) in ovarian cancer patients necessitate further exploration. This study aims to investigate the prognostic role of BMI before chemotherapy in women with ovarian cancer, specifically focusing on PFS and OS.
Methods: A retrospective analysis encompassed 1,136 patients diagnosed with ovarian carcinomas between 1995 and 2018. Patients were categorized based on BMI at presentation, and a comprehensive examination of clinicopathological, treatment, and survival data was conducted.
Results: In the patient population, normal weight patients (BMI < 25 kg/m2) demonstrated a median PFS of 12.8 months (95% CI 11.7-13.9 months), while overweight/obese patients (BMI ≥ 25 kg/m2) exhibited a significantly longer median PFS of 14.9 months (95% CI 13.6-16.4 months, P = 0.006). No statistically significant difference was noted in median OS between the two BMI groups. Subgroup analysis for different histological subtypes revealed a statistically significant benefit for overweight and obese patients with serous and endometrioid histology (mPFS 12.9 months, 95% CI 11.7-14.0 vs. 15.6 months, 95% CI 13.9-17.3, P = 0.012 and 14.6 months 95% CI 13.7-15.5 vs. 25.6 months, 95% CI 9.5-41.7, P = 0.031, respectively). Additionally, BMI ≥ 25 kg/m2 demonstrated a significant advantage in advanced-stage disease.
Conclusions: The study underscores the intricate association between BMI and ovarian cancer prognosis. While a statistically significant difference in progression-free survival was noted between normal weight and overweight/obese patients, with the latter group experiencing a survival benefit, no such difference was observed in overall survival.
期刊介绍：
Nutrients (ISSN 2072-6643) is an international, peer-reviewed open access advanced forum for studies related to Human Nutrition. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
